{"id":"oxycodone-naloxone-combination-prolonged-release","safety":{"commonSideEffects":[{"rate":"10-20%","effect":"Nausea"},{"rate":"5-10%","effect":"Vomiting"},{"rate":"5-10%","effect":"Constipation"},{"rate":"5-10%","effect":"Dizziness"},{"rate":"5-10%","effect":"Headache"}]},"_chembl":null,"_fixedAt":"2026-03-30T18:38:51.416776","_dailymed":null,"mechanism":{"_ai_source":"groq-llama-8b","explanation":"Oxycodone works by activating the mu-opioid receptors in the brain, which helps to reduce pain. Naloxone, on the other hand, works by blocking the mu-opioid receptors, which helps to reverse the effects of oxycodone and prevent overdose.","oneSentence":"Oxycodone is a mu-opioid receptor agonist, while naloxone is a mu-opioid receptor antagonist.","_ai_confidence":"high"},"_scrapedAt":"2026-03-28T01:25:13.317Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Moderate to severe pain"},{"name":"Severe pain for patients who are tolerant to other opioids"}]},"_fixedFields":["modality→Biologic"],"trialDetails":[{"nctId":"NCT02571881","phase":"PHASE4","title":"Opioid Induced Bowel Dysfunction in Patients Undergoing Cesarean Section","status":"UNKNOWN","sponsor":"Kuopio University Hospital","startDate":"2012-10","conditions":"Constipation, Pain, Postoperative","enrollment":57},{"nctId":"NCT01971632","phase":"PHASE3","title":"A Randomised, Double Blind, Placebo and Active Controlled, Double Dummy,Parallel Group Study to Determine the Safety and Efficacy of Oxycodone/Naloxone Prolonged Release Tablets in Subjects With Moderate to Severe, Chronic Nonmalignant Pain","status":"COMPLETED","sponsor":"Mundipharma Research GmbH & Co KG","startDate":"2005-01","conditions":"Subjects With Moderate to Severe, Chronic Nonmalignant Pain","enrollment":463},{"nctId":"NCT01438567","phase":"PHASE3","title":"A Study to Demonstrate Improvement in Symptoms of Constipation in Subjects That Require Around-the-clock Opioid Pain Killer Therapy","status":"COMPLETED","sponsor":"Mundipharma Research GmbH & Co KG","startDate":"2011-09","conditions":"Pain, Constipation","enrollment":270},{"nctId":"NCT02321397","phase":"PHASE2, PHASE3","title":"To Demonstrate Equivalence in Analgesic Efficacy & Bowel Function Between OXN PR Higher Dose & Lower Dose Tablet Strengths in Subjects With Non-cancer or Cancer Pain","status":"COMPLETED","sponsor":"Mundipharma Research GmbH & Co KG","startDate":"2014-11","conditions":"Malignant Pain, Non-malignant Pain","enrollment":155},{"nctId":"NCT02573922","phase":"PHASE4","title":"Opioid Induced Bowel Dysfunction in Patients Undergoing Spinal Surgery","status":"COMPLETED","sponsor":"Kuopio University Hospital","startDate":"2012-05","conditions":"Constipation","enrollment":180},{"nctId":"NCT01014559","phase":"PHASE3","title":"Efficacy of Oxycodone/Naloxone(OXN), Versus Oxycodone (OXY), for the Reduction of Intensity of Opioid-induced Constipation in Pain Patients","status":"TERMINATED","sponsor":"Mundipharma SAS","startDate":"2010-02","conditions":"Constipation, Pain","enrollment":225},{"nctId":"NCT01710904","phase":"","title":"A Non-interventional, Observational Study for Targinact® Treatment in Patients With Chronic Severe Pain","status":"COMPLETED","sponsor":"Mundipharma CVA","startDate":"2012-09","conditions":"Chronic Severe Pain","enrollment":68},{"nctId":"NCT01167127","phase":"PHASE3","title":"Oxycodone/Naloxone (OXN) Combination in Moderate to Severe Non-malignant Pain","status":"COMPLETED","sponsor":"Mundipharma Pharmaceuticals B.V.","startDate":"2009-06","conditions":"Pain","enrollment":113},{"nctId":"NCT01167699","phase":"PHASE3","title":"Oxycodone/Naloxone (OXN) Combination in Moderate to Severe Non-malignant Pain","status":"COMPLETED","sponsor":"Mundipharma Pharmaceuticals B.V.","startDate":"2009-06","conditions":"Pain","enrollment":174},{"nctId":"NCT00944697","phase":"PHASE2","title":"A Study to Demonstrate the Analgesic Efficacy of Oxycodone/Naloxone Prolonged Release Tablets in Addition to Pregabalin Compared to Pregabalin Alone in Opioid-naïve Subjects Treated With Pregabalin Suffering From Moderate to Severe Pain Due to Diabetic Polyneuropathy","status":"COMPLETED","sponsor":"Mundipharma Research GmbH & Co KG","startDate":"2009-07","conditions":"Moderate to Severe Pain Due to Diabetic Polyneuropathy","enrollment":98},{"nctId":"NCT00784810","phase":"PHASE4","title":"A Study to Compare Oxycodone/Naloxone Prolonged Release Against Codeine/Paracetamol in the Treatment of Moderate to Severe Chronic Low Back Pain or Pain Due to Osteoarthritis","status":"COMPLETED","sponsor":"Napp Pharmaceuticals Limited","startDate":"2009-02","conditions":"Osteoarthritis, Back Pain","enrollment":247}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":91,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"phase_3","status":"active","brandName":"Oxycodone & naloxone combination, prolonged release","genericName":"Oxycodone & naloxone combination, prolonged release","companyName":"Mundipharma Research GmbH & Co KG","companyId":"mundipharma-research-gmbh-co-kg","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Oxycodone is a mu-opioid receptor agonist, while naloxone is a mu-opioid receptor antagonist. Used for Moderate to severe pain, Severe pain for patients who are tolerant to other opioids.","enrichmentLevel":3,"visitCount":1,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}